Evidence-based peptide information for research and educational purposes only.
Navaro HealthNavaro Health
Bioregulators & Organ Support

Epithalon (Epitalon)

← Back to Library
Protocol not independently verified FDA safety flag Longevity Circadian
Educational reference only. Read the full disclaimer. The protocols below are not automatically an FDA-approved or clinically verified regimen unless explicitly marked as label-verified or human-trial protocol above.

Compound Profile

Epithalon (Epitalon) is reviewed here for organ-support and bioregulator research.

Research Summary

Evidence Strength Very limited
Primary Evidence

Safety notices, literature searches, limited protocol data

Research Focus

Organ-support research, Tissue signaling

Mechanism

Target context: TERT

Long-Term Data

Limited, unclear, or affected by safety flags.

Current Consensus

Claims need extra caution because evidence is thin or safety flags apply.

Route(s) Subcutaneous
Typical dose 5 mg
Dosing window Pre-Bed
Receptor / target TERT
Properties Not listed
Pre-mixed No

Protocols

Standard Protocol

TimeframeDoseNotes
Days 1-205 mg 1x dailyComplete 20 consecutive days. Administer at bedtime to align with natural pineal melatonin synthesis window. Repeat twice yearly (every 6 months).

Protocol example for research-context comparison; verify against the evidence status and listed medical sources.

Alternative Titration 1: Anecdotal Pulse Protocol (not an Epithalamin study protocol)

TimeframeDoseNotes
Day 110mg 1x daily at bedtimeSite-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 510mg 1x daily at bedtimeSite-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 910mg 1x daily at bedtimeSite-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 1310mg 1x daily at bedtimeSite-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 1710mg 1x daily at bedtimeSite-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 2110mg 1x daily at bedtimeSite-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 2510mg 1x daily at bedtimeSite-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.

Site-provided alternative protocol; the 10 mg Epithalon pulse is not established by Epithalamin studies.

Alternative Titration 2: High-Uncertainty Intensive Protocol

TimeframeDoseNotes
Days 1-1010mg 1x daily at bedtimeHigh-uncertainty site-only entry. The 10 mg/day figure is not established by the classic Epithalamin literature and should not be presented as proven human Epithalon dosing.

Site-provided alternative protocol; high-dose Epithalon use is not established by Epithalamin studies.

Alternative Titration 3: Longevity Foundation Stack (inspired by pineal/thymic bioregulator literature, not a direct replication)

TimeframeDoseNotes
Days 1-105mg Epithalon SC at bedtime + 10mg Thymalin SC at any time + DSIP 100-500mcg SC at bedtime (30 min before Epithalon)Three-compound concurrent protocol inspired by the pineal/thymic bioregulator literature, but not a direct replication because the classic studies used Epithalamin rather than synthetic Epithalon. DSIP administered first at bedtime to initiate delta wave sleep induction; Epithalon administered 30 minutes later to align with the deepening slow-wave sleep window. Thymalin can be administered at any time of day. Separate injection sites for each compound. Baseline immune panel (CD3/CD4/CD8/NK) and telomere length assessment before initiating.
Days 11-205mg Epithalon SC at bedtime + DSIP 100-500mcg SC at bedtimeThymalin standard course completes at Day 10. Continue Epithalon full 20-day standard course with DSIP support throughout. The sequential completion of Thymalin before Epithalon should not be described as a direct Khavinson-study replication.

Site-provided alternative protocol; not a direct replication of Epithalamin studies.

Alternative Titration 4: Senolytic Synergy Protocol: Epithalon + FOXO4-DRI (Goal: combine telomerase-mediated prevention of future senescent cell accumulation (Epithalon) with active clearance of existing senescent cells (FOXO4-DRI); most mechanistically complete cellular aging intervention in the database)

TimeframeDoseNotes
Days 1-31.5 mg/kg FOXO4-DRI SC on Days 1, 2, and 3FOXO4-DRI senolytic pulse first. Run FOXO4-DRI standard 3-day clearing course before Epithalon initiation. Rationale: clear existing senescent cell burden before activating telomerase to protect new cell generations: clearing the old first, then protecting the new.
Days 4-235mg Epithalon SC 1x daily at bedtimeBegin Epithalon standard 20-day course immediately following FOXO4-DRI clearing course. The cleared cellular environment allows Epithalon's TERT activation to act on the surviving non-senescent cell population without competition from the high oxidative and inflammatory burden of the pre-existing senescent cell mass.

Alternative research-context example; not an approved-label regimen unless marked above.

Alternative Titration 5: Circadian Restoration and Melatonin Axis Protocol (Goal: prioritize pineal melatonin rhythm normalization and circadian amplitude restoration; indicated for subjects with severe circadian dysfunction, poor sleep architecture, shift work history, or measured low nocturnal melatonin output; complements Endoluten oral cytomedin)

TimeframeDoseNotes
Days 1-52.5mg Epithalon SC at bedtimeHalf-dose titration entry for subjects whose primary goal is circadian restoration rather than maximum TERT activation. Lower dose reduces vivid dream intensity in first days while melatonin rhythm re-establishes. Baseline salivary DLMO melatonin test before initiating.
Days 6-205mg Epithalon SC at bedtimeFull standard dose for remainder of course. Combine with Endoluten 2 capsules before dinner on Days 1-30 for comprehensive pineal cytomedin (Endoluten) + defined synthetic peptide (Epithalon) coverage of the pineal aging axis simultaneously. Salivary melatonin DLMO retest at Day 30.

Alternative research-context example; not an approved-label regimen unless marked above.

Protocol logic check

Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older, regional, or weakly indexed evidence. Entry context: target (TERT); route Subcutaneous; timing Pre-Bed. Unapproved or unverified dosing examples are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Do not treat Epithalamin studies as direct Epithalon dosing proof. Epithalamin is a pineal extract/bioregulator; Epithalon/Epitalon is the synthetic AEDG tetrapeptide. The popular 10 mg/day claim is not established by the classic Russian/Ukrainian Epithalamin literature, so the protocol notes flag high-dose entries as site-only and high-uncertainty.

Medical literature and study context

Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.

Evidence positionFDA safety-risk context or unapproved compounded-use warning is attached to this entry; no FDA-approved human label was identified for this compound/page context.
Where studiedStudied in organ-specific peptide-bioregulator literature, often with older regional clinical reports plus preclinical or mechanistic studies.
Source systems checkedFDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records
Target and route contextTarget/receptor: TERT. Route(s): Subcutaneous. Dosing window on page: Pre-Bed.
Protocol anchorNo source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
Main evidence limitKey limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty.

Source-linked findings

  • Epithalon/Epitalon literature is concentrated in peptide-bioregulator, telomere, pineal, and aging-model research, including older regional clinical literature and preclinical work.
  • There is no FDA-approved label for general longevity use, so claims should be presented as limited and source-dependent.
  • FDA lists epitalon among withdrawn nominated bulk substances with insufficient route-specific safety information. Major dosing caveat: much of the Russian/Ukrainian human pineal-peptide literature used Epithalamin, a pineal extract/bioregulator, not synthetic Epithalon/Epitalon. Do not convert those papers into a 10 mg/day Epithalon rule.

Protocol and study notes

  • No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
  • On-page protocol examples summarized for comparison: Standard Protocol: Days 1-20, 5 mg 1x daily; Alternative Titration 1: Anecdotal Pulse Protocol (not an Epithalamin study protocol): Day 1, 10mg 1x daily at bedtime.
  • Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty.
  • Monitor metabolic labs, mitochondrial or fatigue endpoints, cancer history, renal/hepatic context, and overstimulation or sleep changes.

Selected medical sources

Independent evidence

Independent safety notes: FDA lists epitalon among withdrawn nominated bulk substances with insufficient route-specific safety information. Major dosing caveat: much of the Russian/Ukrainian human pineal-peptide literature used Epithalamin, a pineal extract/bioregulator, not synthetic Epithalon/Epitalon. Do not convert those papers into a 10 mg/day Epithalon rule.

Regulatory status: unapproved or compounded peptide with FDA safety risk flag

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

  • Active malignancy with rapidly proliferating tumor cells: telomerase activation is the primary mechanism of Epithalon; malignant cells already exploit telomerase (TERT) re-expression as a core immortalization strategy; exogenous TERT stimulation in the context of active cancer could theoretically accelerate tumor cell telomere maintenance and proliferative capacity; use in subjects with known active malignancy requires oncological evaluation.
  • Known TERT-expressing malignancy (most carcinomas, lymphomas, certain sarcomas): same mechanism as above; the subset of cancers most reliant on TERT for immortality represent the highest-risk context for Epithalon use.
  • Known hypersensitivity to Epithalon, epithalamin-derived peptides, or formulation excipients.
  • Pregnancy: the epigenetic and telomeric effects of TERT activation during fetal development are not characterized; pineal gland modulation during organogenesis is not established as safe.
  • Breastfeeding: no safety data.
  • Concurrent use of telomerase inhibitor investigational agents (in oncology trials): Epithalon's TERT activation directly opposes the mechanism of experimental telomerase inhibitor anticancer therapies.
  • Pre-existing conditions of telomere lengthening dysregulation (dyskeratosis congenita variants with TERT gain-of-function): in the rare context of existing TERT hyperactivation pathology, additional TERT stimulation is inadvisable.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

  • Vivid dreams and altered dream intensity: the most consistently reported subjective adverse effect; Epithalon's restoration of pineal melatonin secretion and improvement in slow-wave sleep architecture produces dramatically more vivid, narrative, and emotionally rich dreaming; typically experienced as a positive effect but can be disorienting in subjects with prior dream suppression (common with sleep deprivation or alcohol use).
  • Altered sleep architecture: the first 1-5 days of a new Epithalon cycle may produce transient sleep architecture changes as the pineal melatonin rhythm is re-establishing; subjects may experience unusually deep sleep, difficulty waking at normal times, or altered REM/NREM proportions.
  • Mild transient fatigue: reported in a minority of subjects in the first days of a cycle; likely related to the acute melatonin rhythm normalization.
  • Injection site mild reaction: standard subcutaneous peptide injection response; minimal.
  • Transient mood changes: a small subset of subjects reports mild mood elevation or transient emotional sensitivity during the first week; related to melatonin normalization and its effects on serotonin synthesis pathways (melatonin is downstream of serotonin in pinealocyte biosynthesis).
  • No endocrine disruption beyond pineal normalization: Epithalon does not affect the HPA axis, sex hormones, thyroid, or growth hormone axis directly; all secondary hormonal effects are downstream of the pineal melatonin restoration.
  • No documented toxicity at standard doses in the 40+ year Russian clinical use history: the safety profile of Epithalon across decades of Russian and Ukrainian clinical application is exceptionally clean; no serious adverse events have been documented in the published Khavinson literature at standard protocol doses.
  • Theoretical cancer promotion risk (not documented in clinical data): the TERT activation mechanism raises the theoretical concern above; however, in the 40+ year human use history including elderly subjects (who have the highest background cancer incidence), no increase in cancer rates has been documented: and the published data shows reduced cancer incidence; this remains a mechanistic theoretical concern not supported by the available observational data.

Compatibility

The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

VilonThymalinDSIP (Delta Sleep-Inducing Peptide)FOXO4-DRISelank

Reported contraindicated combinations:

None listed.

Sources